Interleukin-35 pretreatment attenuates lipopolysaccharide-induced heart injury by inhibition of inflammation, apoptosis and fibrotic reactions.

International Immunopharmacology
Huan HuYanqing Wu

Abstract

Previous studies have demonstrated that targeting inflammation is a promising strategy for treating lipopolysaccharide (LPS)-induced sepsis and related heart injury. Interleukin-35 (IL-35), which consists of two subunits, Epstein-Barr virus-induced gene 3 (EBI3) and p35, is an immunosuppressive cytokine of the IL-12 family and exhibits strong anti-inflammatory activity. However, the role of IL-35 in LPS-induced heart injury reains obscure. In this study, we explored the role of IL-35 in heart injury induced by LPS and its potential mechanisms. Mice were treated with a plasmid encoding IL-35 (pIL-35) and then injected intraperitoneally (ip) with LPS (10 mg/kg). Cardiac function was assessed by echocardiography 12 h later. LPS apparently decreased the expression of EBI3 and p35 and caused cardiac dysfunction and pathological changes, which were significantly improved by pIL-35 pretreatment. Moreover, pIL-35 pretreatment significantly decreased the levels of cardiac proinflammatory cytokines including TNF-α, IL-6, and IL-1β, and the NLRP3 inflammasome. Furthermore, decreased number of apoptotic myocardial cells, increased BCL-2 levels and decreased BAX levels inhibited apoptosis, and LPS-induced upregulation of the expression of c...Continue Reading

References

Jul 19, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Hai Ling LiWilbur Y W Lew
Nov 23, 2007·Nature·Lauren W CollisonDario A A Vignali
Jul 28, 2009·Current Opinion in Critical Care·Sergio L Zanotti-Cavazzoni, Steven M Hollenberg
Jan 9, 2010·Circulation Research·Rahul Kakkar, Richard T Lee
Feb 7, 2012·Nature Immunology·Lauren W CollisonDario A A Vignali
May 12, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Masanobu TsudaM Eric Gershwin
Jul 21, 2012·Nature Immunology·Dario A A Vignali, Vijay K Kuchroo
Aug 14, 2012·Vascular Pharmacology·Frans A van Nieuwenhoven, Neil A Turner
Oct 9, 2014·The Journal of Surgical Research·Kengo TomitaYuichi Hattori
Oct 15, 2014·Current Pharmaceutical Design·Yuri V BobryshevDimitry A Chistiakov
Mar 25, 2015·Intensive Care Medicine·Filippo SanfilippoMaurizio Cecconi
Apr 19, 2015·Critical Care : the Official Journal of the Critical Care Forum·Yiyang WangHuadong Wang
Jun 19, 2015·The Journal of Biological Chemistry·Xiaojin ShaXiao-feng Yang
Sep 1, 2015·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Yan LiMingcai Li
Sep 29, 2015·American Journal of Respiratory and Critical Care Medicine·Carolin FleischmannUNKNOWN International Forum of Acute Care Trialists
Oct 8, 2016·Environmental Toxicology and Pharmacology·Liu XianchuDing Yang
Dec 3, 2016·Internal and Emergency Medicine·Francesca InnocentiRiccardo Pini
Dec 30, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xue-Li LuXin-Liang Yao
Oct 4, 2017·Frontiers in Immunology·Yan-Cun LiuYan-Fen Chai
Mar 21, 2018·Journal of Translational Medicine·Baoren ZhangHao Wang
Nov 11, 2018·BMC Pharmacology & Toxicology·Qiang LuoHongjing Guan
Dec 6, 2018·Frontiers in Immunology·Massimo MaddaloniDavid W Pascual
Dec 29, 2018·Expert Review of Clinical Immunology·Man LuoYong Zhou
Aug 31, 2019·The Journal of Pharmacology and Experimental Therapeutics·MingXia DuanQingQing Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis